ARCHIVES

NSABP Trial Finds Raloxifene Equivalent To Tamoxifen For Cancer Risk Reduction

This article is from The Cancer Letter archive.

Vol. 29 No. 4 | April 28, 2006

Download PDF Visit The Full Archive

Related Articles

EntreMed Issued U.S. Patent For Active Parts Of Endostatin.

March 2, 2001

NCI Staff Working Group Leans Toward Starting COP With Community Hospitals As Lead Funding Agencies

January 1, 1982

Advocacy Group Urges FDA to Sift Through Avastin Glioblastoma Data—Agency Accepts

June 14, 2013

Upper Endoscopy Most Effective When Performed in 3-Year Intervals

July 27, 2012

Final Issue Of the Year

December 14, 1990

NCI Begins Latin American Cancer Research Network

April 10, 2009